| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T151 |
0-134 |
Sentence |
denotes |
With regard to COVID-19, there are currently several clinical studies investigating the effects of RAS inhibition and ACE2 regulation. |
| T152 |
135-453 |
Sentence |
denotes |
An ongoing study will assess the impact of ACE inhibitor and ARB treatment on the severity and prognosis of patients with COVID-19 (Hypertension in Patients Hospitalized With COVID-19 [HT-COVID19], NCT04318301; ACE Inhibitors, Angiotensin II Type-I Receptor Blockers and Severity of COVID-19 [CODIV-ACE], NCT04318418). |
| T153 |
454-771 |
Sentence |
denotes |
Along these lines, there are 2 recently launched trials testing the effects of losartan among patients hospitalized with COVID-19 (Losartan for Patients With COVID-19 Requiring Hospitalization; NCT04312009) and those who are ambulatory (Losartan for Patients With COVID-19 Not Requiring Hospitalization; NCT04311177). |
| T154 |
772-1148 |
Sentence |
denotes |
Further studies have been launched to evaluate the effect of continuation versus replacement (Coronavirus [COVID-19] ACEi/ARB Investigation [CORONACION]; NCT04330300) or withdrawal (ACE Inhibitors or ARBs Discontinuation in Context of SARS-CoV-2 Pandemic [ACORES-2]; NCT04329195) of RAS inhibitors on the clinical outcomes in patients with cardiovascular disease and COVID-19. |
| T155 |
1149-1370 |
Sentence |
denotes |
There is also an ongoing pilot study assessing the effects of rhACE2 treatment in patients with COVID-19 (Recombinant Human Angiotensin-converting Enzyme 2 [rhACE2] as a Treatment for Patients With COVID-19; NCT04287686). |
| T156 |
1371-1488 |
Sentence |
denotes |
Currently, there is no data to support any conclusive effects of the use of RAS inhibitors in patients with COVID-19. |
